Transapical aortic valve implantation in patients with poor left ventricular function and cardiogenic shock  by Unbehaun, Axel et al.
Unbehaun et al Acquired Cardiovascular DiseaseTransapical aortic valve implantation in patients with poor
left ventricular function and cardiogenic shockAxel Unbehaun, MD, Miralem Pasic, MD, PhD, Semih Buz, MD, Stephan Dreysse, MD,
Marian Kukucka, MD, PhD, Roland Hetzer, MD, PhD, and Thorsten Drews, MD, PhDFrom th
Disclos
Unbe
autho
Receive
publi
Address
Augu
0022-52
Copyrig
http://dxObjectives: In line with our institutional no exclusion policy we accept patients with very poor left ventricular
performance and cardiogenic shock for transcatheter aortic valve implantation (TAVI). The purpose of our study
was to analyze outcome in these patients and to identify what happens to the left ventricular function after TAVI
in patients with failing ventricles.
Methods:Between April 2008 and August 2013, 730 patients underwent transapical TAVI at our institution. The
study group consisted of all 104 patients who presented with severely depressed left ventricular function, defined
as left ventricular ejection fraction (LVEF) 30%. Based on the Society of Thoracic Surgeons predicted risk of
mortality, the arithmetic risk for surgery in the study cohort was 23% 19% (2%-90%), and 23 patients (22%)
were in cardiogenic shock.
Results: Excluding patients in cardiogenic shock, the survival rates in the study group at 1, 2, and 4 years were
81%  5%, 65%  6%, and 45%  8%, respectively. Patients in cardiogenic shock showed significantly
worse outcome (P ¼ .048). Improvement in LVEF of 50% or more was found in 74 patients (71%) and
100% or more improvement in 45 patients (43%). Early improvement in LVEF was significantly (P ¼ .049)
greater in patients with preoperative values of LVEF  20%.
Conclusions: In the majority of patients with failing ventricles, left ventricular function is quickly restored after
TAVI and elimination of aortic stenosis. Without the additional trauma of cardioplegic arrest, TAVI is the
potentially superior treatment option in patients with poor and very poor left ventricular performance. (J Thorac
Cardiovasc Surg 2014;148:2877-82)A
C
DSupplemental material is available online.
According to recently reported registry data,1,2 7% to 9% of
patients referred for transcatheter aortic valve implantation
(TAVI) present with left ventricular ejection fraction
(LVEF) below 30%. In view of the higher operative
mortality rate3 and the grave prognosis if the aortic valve pa-
thology is left untreated,4 TAVI has already been performed
as an alternative treatment in these patients but it is still the
subject of controversial discussion or has even been
considered by recent guidelines to be contraindicated.5
In line with our institutional no exclusion policy6 we
accept patients with very poor left ventricular performance7
and cardiogenic shock8 for TAVI. The purpose of our studye Deutsches Herzzentrum Berlin, Berlin, Germany.
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The Journal of Thoracic and Carwas to analyze outcomes in these patients and to identify
what happens to the left ventricular function after TAVI in
patients with failing ventricles. This study represents an
update of our preliminary report in this field.7PATIENTS AND METHODS
Patients and Study Design
This was a retrospective, observational, single-center, cohort study
of prospectively and retrospectively collected data. The institutional
review board at our institution approved the study and all patients or their
representatives gave informed consent.
Between April 16, 2008, and August 1, 2013, 730 consecutive patients
underwent a planned transapical TAVI procedure at our institution with a
balloon-expandable prosthesis (Sapien THV or XT type; Edwards
Lifesciences, LLC, Irvine, Calif). Thewhole institutional process of patient
selection, the inclusion and exclusion criteria, the diagnostic workup, and
the selection of the access site have been described in detail in previous
publications.6,9 All patients were evaluated by the institutional TAVI
team and accepted for the procedure according to the team consensus.
Patients with an extreme risk profile or cardiogenic shock were not
excluded. The only exclusion criteria for TAVI were signs of active
aortic valve endocarditis or too large an annulus. All patients completed
at least the 30-day follow-up period.
Study Cohort
The study cohort included all 104 consecutive patients of this
institutional cohort (14.2%) who presented with LVEF between 10%
and 30%. The preoperative characteristics of the study cohort are given
in Table 1.diovascular Surgery c Volume 148, Number 6 2877
Abbreviations and Acronyms
BAV ¼ balloon aortic valvuloplasty
CPB ¼ cardiopulmonary bypass
LVEDD ¼ left ventricular end diastolic diameter
LVEF ¼ left ventricular ejection fraction
TAVI ¼ transcatheter aortic valve implantation
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As we explained in a previous report,8 cardiogenic shock was diagnosed
only if all the following criteria were present: unstable hemodynamic con-
dition and requirement of increasing doses of adrenaline and upcoming or
evident multiorgan failure, including oligoanuria and pulmonary conges-
tion at chest radiography. Based on this definition, cardiogenic shock was
diagnosed in 23 patients of the study cohort (22.1%). In patients with
cardiogenic shock, the median Society of Thoracic Surgeons predicted
risk of mortality was 38.7% (interquartile range [IQR], 22.2%-62.1%;
range, 8.1%-89.5%). Stages III to V of renal failure (ie, glomerular filtra-
tion rate 0-59 mL/min) were present in 18 patients with cardiogenic shock
(78.3%). Seven patients with shock (30.4%) needed respirator support
preoperatively. An intra-aortic balloon pump was preoperatively present
or its intraoperative implantation was electively planned in 8 patients
(34.8%). The median N-terminal probrain natriuretic peptide level was
1.7 104 pg/mL (IQR, 11,345-28,416 pg/mL; range, 1323-77,019 pg/mL).
Implantation Procedure and Elective Use of
Cardiopulmonary Bypass (CPB)
All TAVI procedures were performed in our hybrid operating room by a
consistent heart team using a principal surgical technique10 with some
modifications.11 A monoplane angiographic system (Artis zee, Siemens
AG, Munich, Germany) was used. The whole procedure was guided by
transesophageal echocardiography.
In accordance with our institutional policy, the elective use of CPB was
considered in patients with cardiogenic shock, very poor left ventricular
function (LVEF < 20%), enlarged right ventricles related to severe
pulmonary hypertension, and in patients with planned combined surgical
intervention.6 For cannulation, the femoral vessels were exposed
surgically.12 The final decision about the use of CPB was made in the oper-
ating room after review of all aspects of preoperative diagnostics by the
members of the implanting team and after meticulous evaluation of heart
function by means of intraoperative transesophageal echocardiography.
Our institutional strategy has been described in detail elsewhere.6-9,12
Selection of the Prosthesis Size and Treatment of
Intraprocedural Regurgitation
The recommendations of the valve manufacturer were in general
applied: a 23-mm prosthesis was used for aortic annulus diameter—as
assessed by transesophageal echocardiography—of between 18 and 22
mm, a 26-mm prosthesis for annulus diameter of between 21 and 25 mm,
and a 29-mm prosthesis (after introduction of the Sapien XT type) for
annulus diameter of between 24 and 27 mm. In borderline cases, multislice
computed tomography measurements in multiple planes influenced valve
size selection. Intraprocedural regurgitationwas precisely graded according
to the guidelines and treated according to our institutional policies.6 In the
presence of relevant regurgitation, additional curative measures (such as
redilation or implantation of a second prosthesis) were taken.
Evaluation of Left Ventricular Function
Left ventricular function was assessed preoperatively by means
of transthoracic echocardiography or transesophageal echocardiography.2878 The Journal of Thoracic and Cardiovascular SurLeft ventricular end diastolic diameter (LVEDD) and LVEF were
measured and prospectively stored in the institutional TAVI database.
Postoperatively, transthoracic echocardiography measurements were
performed-—usually within the first postoperative week—on a routine
basis. Postoperative values of LVEF and LVEDD were collected
retrospectively. Differences to preoperative values in absolute numbers
and as a percentage of preoperative values were calculated.
Follow-up
The follow-up regarding death or survival was 100%. Official
information regarding death was also obtained from the state administra-
tive office. For all patients domiciled in Germany, information was
obtained from the German Register of Residents. All patients from foreign
countries were contacted via telephone, E-mail, or letter. The date of the
last contact was recognized. This study is reported according to the updated
standardized end point definitions of the Valve Academic Research
Consortium-2.13
Statistical Analysis
Continuous variables are presented as mean  standard deviation or
medians, IQR, and minimum-maximum range. Categorical variables are
described as numbers and percentages. Several parameters of left
ventricular function are presented as box-whisker plots. Differences in
LVEF and LVEDD before and after the procedure were analyzed using
the Wilcoxon signed-rank test. Differences between patients with very
poor LVEF (10%-20%) and patients with poor LVEF (21%-30%) were
analyzed using the Mann-Whitney U test, Fisher exact test, or the
McNemar test. The Kaplan-Meier survival functions were calculated. A
log-rank test was performed to analyze differences between subgroups.
A Cox proportional hazards model was used to investigate possible risk
factors for mortality. A univariable approach for all possible risk factors
was evaluated. Proportional hazard assumptions were checked. For several
parameters, multivariable Cox proportional hazards models with all
combinations were performed. The best model was chosen according to
Akaike’s information criterion. The data were evaluated using IBM
SPSS Statistics software, version 19 (IBM SPSS Inc, Armonk, NY) and
R 2.15 statistics software (R Foundation for Statistical Computing, Vienna,
Austria).RESULTS
Intraprocedural Course in Study Cohort
A balloon-expandable prosthesis was implanted in all
patients; 46 patients (44.2%) received the Sapien XT type
prosthesis and 58 patients (55.8%) received the THV type
prosthesis. A 23-mm prosthesis was implanted in 18
patients (17.3%), a 26-mm prosthesis was implanted in
55 patients (52.9%), and a 29-mm prosthesis was implanted
in 31 patients (29.8%). To reduce or eliminate relevant
intraprocedural regurgitation, redilation was performed in
5 patients (4.8%) and a second TAVI prosthesis was
implanted in 3 patients (2.9%). There was no severe
postprocedural regurgitation and in no case was there
the need to convert to conventional surgery because of
untreatable regurgitation.
Valve deployment was performed with elective use of
CPB in 30 patients (28.8%). The median radiation time
was 6.0 minutes (IQR, 4.5-9.7 minutes; range, 2.1-65.3
minutes). Simultaneous elective percutaneous coronary
artery stenting was performed in 14 patients (13.5%) withgery c December 2014
TABLE 1. Preoperative characteristics of study cohort (N ¼ 104)
Characteristic Median/n
Interquartile
range/
ratio (%)
Minimum-
maximum
Male/female 63/41 60.6/39.4 —
Age (y) 79 73-84 29-93
Height (cm) 170 164-175 145-187
weight (kg) 74 64-85 42-119
Body mass index 25 23-28 19-43
Body surface area (m2) 1.87 1.71-2.01 1.32-2.38
Additive EuroSCORE 15 13-18 5-25
Logistic EuroSCORE (%) 60 39-80 4-97
EuroSCORE II (%) 33 18-52 2-95
STS PROM score (%) 17 10-26 2-90
STS MoM score (%) 54 39-69 19-97
NYHA class IV 68 65.4 —
Cardiogenic shock 23 22.1 —
NT-proBNP (pg/mL) 10,758 4268-17,941 1064-93,605
Troponin I (mg/mL) 0.06 0.02-0.10 0.00-83.00
FEV1 (L) 1.6 1.2-2.3 0.6-3.3
IVC (L) 1.9 1.5-2.5 0.7-3.6
Diabetes mellitus 34 32.7 —
PAD 72 69.2 —
s/p stroke, neurologic
disease
29 27.9 —
Creatinine clearance
(mL/min)
51 33-62 0-175
Dialysis 6 5.8 —
Systolic PAP>50 mm Hg 66 63.5 —
Atrial fibrillation 38 36.5 —
Coronary artery disease 68 65.4 —
s/p PCI 25 24.0 —
s/p CABG 27 26.0 —
s/p AVR 7 6.7 —
s/p MVR 2 1.9 —
Pacemaker/ICD 21 20.2 —
LVEF (%) 25 20-30 10-30
LVEF  20% 42 40.4 —
LVEDD (mm) 57 51-63 38-80
MR moderate/severe 36 34.6 —
TR moderate/severe 19 18.3 —
Aortic calcification
moderate/severe
36 41.3 —
EuroSCORE, European System for Cardiac Operative Risk Evaluation; STS PROM,
Society of Thoracic Surgeons predicted risk of mortality; STS MoM, Society of
Thoracic Surgeons predicted risk of morbidity or mortality; NYHA, New York Heart
Association; NT-proBNP, N-terminal probrain natriuretic peptide; FEV1, forced
expiratory volume in 1 second in liters (L); IVC, inspiratory vital capacity in liters
(L);PAD, peripheral arterial disease; s/p, status post;PCI, percutaneous coronary inter-
vention;CABG, coronary artery bypass grafting; AVR, aortic valve replacement;MVR,
mitral valve repair/replacement; ICD, implantable cardioverter defibrillator; LVEF, left
ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter;
MR, mitral regurgitation; TR, tricuspid regurgitation; PAP, pulmonary artery pressure.
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Dconcomitant coronary artery disease. Excluding patients
with simultaneous coronary artery stenting, the median
amount of contrast agent was 86 mL (IQR, 70-115 mL;
range, 40-260 mL). Including patients with combined
planned surgical interventions, the median proceduralThe Journal of Thoracic and Cartime was 105 minutes (IQR, 85-145 minutes; range,
30-415 minutes).
Echocardiographic Parameters and Myocardial
Recovery
Median LVEF increased significantly (P< .001) from
25% (IQR, 20%-30%; range, 10%-30%) to 40% (IQR,
30%-50%; range, 20%-65%). In relation to the
preoperative value, a 50% increase or more in LVEF was
observed in 74 patients (71.2%) and a 100% increase or
more in 45 patients (43.3%) (Figure 1). Median LVEDD
decreased significantly (P < .001) from 57 mm (IQR,
51-63 mm; range, 38-80 mm) to 54 mm (IQR, 51-60 mm;
range, 35-73 mm). There was significantly (P ¼ .049)
more increase in LVEF in patients with very poor LVEF
(Figures E1 and E2). Median effective orifice area
increased significantly (P< .001) after valve deployment
from 0.6 cm2 (IQR, 0.6-0.8 cm2; range, 0.5-1.8 cm2) to
2.3 cm2 (IQR, 1.8-2.6 cm2; range, 0.8-3.7 cm2).
Thirty-Day Outcome in Study Cohort
The overall 30-day mortality rate in patients with LVEF
of 10%-30% was 5.8%; 6 patients died during the first
30 days after the TAVI procedure. Excluding the 23 patients
in cardiogenic shock, the 30-day mortality rate was 3.7%; 3
of 81 patients died during the first 30 days. Aspects related
to 30-day outcome and complication rates according to the
Valve Academic Research Consortium-2 criteria13 are sum-
marized in Table 2.
Survival in Study Cohort
The overall survival rates at 1, 2, and 4 years were 72.9%
 4.6%, 60.5% 5.4%, and 41.8% 6.8%, respectively.
Excluding the 23 patients in cardiogenic shock, the
survival rates at 1, 2, and 4 years were 81.0%  4.6%,
65.1%  6.1%, and 45.0%  7.8%, respectively. Patients
without cardiogenic shock showed better (P ¼ .047)
survival than patients in cardiogenic shock. The preopera-
tive status of very poor LVEF (10%-20%) failed to be
predictive for follow-up mortality (hazard ratio, 1.02;
95% confidence interval, 0.55-1.87; P ¼ .959). The
Kaplan-Meier survival functions are shown in Figure 2.
Significant predictors of follow-up mortality in univariable
and multivariable analysis are given in Table 3.
DISCUSSION
Outcome After TAVI in Patients With Poor Left
Ventricular Performance
Despite the fact of very low early mortality, we observed
an overall 1-year survival rate of 73% in our study cohort of
104 patients with an LVEF 10% to 30%. The observed
mortality during the first year was mainly governed by
cardiogenic shock, with the better 1-year survival rate of
81% in nonshock patients. Control group patients with andiovascular Surgery c Volume 148, Number 6 2879
FIGURE 1. Left ventricular ejection fraction (LVEF) and left ventricular end diastolic diameter (LVEDD) preoperatively and before discharge from
hospital as assessed by echocardiography. preop, Preoperatively; postop, postoperatively.
Acquired Cardiovascular Disease Unbehaun et al
A
C
DLVEF> 30% showed better survival but not until after
about 1.5 years. Based on the known desperate prognosis
if only medical management is offered, with <50%
1-year survival in patients with LVEF  40%,4 a clear
benefit of a TAVI strategy in nonsurgically managed
patients becomes evident. Furthermore and despite a
tremendously higher risk profile in our study cohort, weTABLE 2. Procedural, periprocedural, and 30-day outcome in the
study cohort (N ¼ 104), according to Valve Academic Research
Consortium criteria13
Outcome N Ratio (%)
Conversion to surgical AVR 0 0.0
Unplanned use of CPB 1 1.0
TAV-in-TAV deployment 3 2.9
Moderate PPM 6 5.8
Severe PPM 2 1.9
TAV moderate regurgitation 1 1.0
TAV severe regurgitation 0 0.0
Periprocedural/spontaneous MI 0 0.0
Disabling stroke 0 0.0
Nondisabling stroke 2 1.9
Life-threatening/disabling bleeding 5 4.8
Major bleeding 9 8.7
AKI stage I 13 12.5
AKI stage II/III 7 6.7
Renal replacement therapy 6 5.8
Major access-related complications 4 3.8
Minor access-related complications 3 2.9
New pacemaker implantation 6 5.8
Device success criterion (success; 30-d) 96 92.3
Early safety criterion (failure; 30-d) 16 15.4
All-cause mortality (30-d) 6 5.8
All-cause mortality (excluding shock; 30-d) 3 3.7
AVR, Aortic valve replacement; CPB, cardiopulmonary bypass; TAV, transcatheter
aortic valve; PPM, prosthesis-patient mismatch; MI, myocardial infarction; AKI,
acute kidney injury.
2880 The Journal of Thoracic and Cardiovascular Surobserved better outcome than in cohorts with LVEF
 40% treated with surgical valve replacement, which
had 1-year survival of about 60% to 70%.3,14 On that
account and further based on our no exclusion policy,
TAVI became our primary choice of treatment in these
patients soon after its introduction at our institution.6,7
In recent studies, the important prognostic value of a low
flow state (defined as stroke volume index 35 mL/m2)
rather than LVEF alone has been shown.15-17 Although
our study design did not consider stroke volume index,
significant similarities in several patients’ characteristics
exist: mean LVEF 23%  6%, indexed effective orifice
area 0.6 cm2/m2 in 99 patients (95.2%), and low
gradient with mean gradient 40 mm Hg in 65 patients
(62.5%) and mean gradient 20 mm Hg in 20 patients
(19.2%) of our study cohort. O’Sullivan and colleagues15
observed in 61 patients with low gradient aortic stenosis
and LVEF  40% a 1-year mortality rate of 24.5%. The
pioneering Canadian group described a 1-year mortality
of about 35% in 90 patients with low-flow-low gradient
aortic stenosis and LVEF< 50%.16 Among 225 patients
from the Placement of Aortic Transcatheter Valves trial
with low flow aortic stenosis and LVEF<50% (excluding
patients with LVEF< 20%), a 2-year mortality rate of
48.7% was found.17 Because of the prognostic value, we
fully agree with all these groups that a measure of stroke
volume index should be included in the evaluation of
TAVI candidates. Despite higher mortality rates in low-
flow patients, one may summarize these studies and
conclude that especially critical patients profit most from
a comprehensive therapeutic strategy. Otherwise, if they
are left untreated, their prognosis is grave.
Our study cohort contained a high proportion of patients
with acute decompensation, catecholamine dependence,
and cardiogenic shock. Therefore, we observed a highergery c December 2014
FIGURE 2. Kaplan-Meier survival functions in patients with different preoperative left ventricular ejection fraction (LVEF). TAVI, Transcatheter aortic
valve implantation.
Unbehaun et al Acquired Cardiovascular Diseasearithmetic risk profile, more patients in New York Heart
Association functional class IV, and significantly more
patients with severe pulmonary hypertension. Decompensa-
tion in aortic stenosis is a potentially fast, ongoing process.
Therefore, almost all our patients were treated with an
urgent indication and often with an emergency indication.A
C
DCardiogenic Shock
Treatment of patients with severe aortic stenosis and
cardiogenic shock remains a medical and surgical
challenge. As we have already stated, TAVI is a realistic
lifesaving option for these patients who would otherwise
die.8 On the other hand, one may criticize the large amount
of resources used and the fact that more than half of
patients were lost within the first year. Our ethos is to
concentrate on the>40% of patients who survive the first
year with relatively good further prognosis. Saving these
patients’ lives can succeed only if there is no fear of
recruiting all efforts. Of course, a tailored strategy and aTABLE 3. Predictors of follow-up mortality
Hazard
ratio
95% Confidence
interval P value
Univariable analysis
Additive EuroSCORE 1.12 1.03-1.22 .010
Logistic EuroSCORE 1.02 1.00-1.03 .021
EuroSCORE II 1.02 1.01-1.03 .003
STS PROM score 1.03 1.01-1.04 .001
Cardiogenic shock 1.91 1.99-3.67 .052
s/p CABG 1.86 0.98-3.55 .060
Absence of AKI 0.52 0.27-1.02 .056
Multivariable analysis
s/p CABG 2.11 1.09-4.09 .027
Cardiogenic shock 2.17 1.11-4.22 .023
EuroSCORE, European System for Cardiac Operative Risk Evaluation; STS PROM,
Society of Thoracic Surgeons predicted risk of mortality; s/p, status post; CABG,
coronary artery bypass graft; AKI, acute kidney injury.
The Journal of Thoracic and Carmultidisciplinary approach are mandatory to achieve
satisfactory results.8Role of CPB
In accordance with our institutional policy, the elective
use of CPB was considered in patients with cardiogenic
shock, very poor left ventricular function (LVEF<20%),
enlarged right ventricles related to severe pulmonary
hypertension, and in patients with planned combined
surgical intervention.6 Under these critical circumstances,
we consider the elective application of CPB a useful tool
to prevent resuscitation because of ventricular fibrillation
and to allow myocardial recovery.12 Among patients with
elective use of CPB, we did not observe a negative effect
on procedural or postprocedural variables. Furthermore,
the emergency use of CPB with known worse outcome
was rare (1%) in our study cohort of patients with LVEF
between 10% and 30%.Instant Myocardial Recovery Following TAVI
We observed an effect of instant myocardial recovery in
the majority of our patients, with a more pronounced
increase in LVEF in patients with very poor left ventricular
performance. Clavel and colleagues18 described better
myocardial recovery at discharge and at 1 year in the
TAVI cohort with LVEF  50% compared with patients
treated with surgical valve replacement. Their study found
female gender, absence of atrial fibrillation, baseline
LVEF, TAVI therapy, increase in aortic valve area, and
absence of need for coronary revascularization to be inde-
pendent predictors of LVEF recovery, whereas myocardial
contractile reserve failed to be predictive for recovery. We
fully agree with the philosophy behind their concept:
Avoiding the additional trauma of cardioplegic arrest is
beneficial for myocardial recovery in patients with signifi-
cantly impaired LVEF.diovascular Surgery c Volume 148, Number 6 2881
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Based on our no exclusion policy, we do not refuse TAVI
to patients with high comorbidity status or profound shock.6
Soon after the introduction of TAVI at our institution, it
became our primary choice of treatment in patients with
poor or very poor left ventricular performance.7 Unlike
solely palliative balloon aortic valvuloplasty (BAV), TAVI
eliminates aortic valve stenosis completely (instead of
only partially) and without significant additional trauma.
We consider complete elimination of stenosis (without
residual regurgitation) a prerequisite to allow early myocar-
dial recovery followed by restoration of dependent organ
function. Because BAV also requires rapid pacing, we are
convinced that the trauma to critical patients is not
significantly reduced by using solely palliative BAV. In
addition, BAV only reduces aortic valve stenosis instead
of completely eliminating it. Furthermore, it carries the
risk of relevant aortic valve insufficiency remaining after
BAV. Both factors could complicate myocardial recovery.
Since the introduction of TAVI at our institution, we have
never favored BAV instead of TAVI. Contrary to surgical
valve replacement under these circumstances, TAVI
allows elimination of aortic valve stenosis without aortic
crossclamping and cardioplegic arrest—a more gentle
concept for a stressed myocardium and for patients with a
relatively high operative mortality.
Study Limitations
Our study has 3 major limitations: it is based only on
transapical TAVI and is further limited to 1 type of
balloon-expandable prostheses. On the other hand, a major
benefit of our study design is the consistent dataset and the
large number of patients treated with 1 identical strategy by
a permanent team. Out of clinical concerns in critical
patients, we waived any preoperative evaluation of myocar-
dial contractile reserve. Also, our analysis of postoperative
myocardial recovery solely focused on the early postopera-
tive period and did not consider long-term changes of
parameters of left ventricular performance.
CONCLUSIONS
In the majority of patients with failing ventricles, left
ventricular function is quickly restored after TAVI and
elimination of aortic stenosis. Without the additional
trauma of cardioplegic arrest, TAVI is the potentially
superior treatment option in patients with poor and very
poor left ventricular performance.
Adam Penkalla, MD, Anneke Damberg, MD, Alexander
Mladenow, MD, and Christoph Klein, MD, PhD, are also members
of the TAVI team who contributed to data collection and data2882 The Journal of Thoracic and Cardiovascular Surinterpretation for this study. The authors thank Julia Stein for
providing advice and support in statistical analyses and Anne
Gale for editorial assistance.
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FIGURE E1. Postoperative changes in left ventricular ejection fraction (DLVEF) and left ventricular end diastolic diameter (DLVEDD) in patients with poor
and very poor preoperative (preop) left ventricular performance.
FIGURE E2. Fluctuation plot of postoperative changes in left ventricular ejection fraction (LVEF) in patients with poor and very poor preoperative left
ventricular performance. Absolute numbers of patients are given (difference to study cohort numbers caused by in-hospital mortality). preop, Preoperatively;
postop, postoperatively.
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